Furthermore, in all mice, this therapeutic approach caused high number of CD4+ IFN-γ+ T-cells (Th1 cells) and CD8+ IFN-γ+ cells contributing to the full rejection of tumor (Shindo et al., 2015[86]). The gene discussed is IFNG; the disease is neoplasm.